Blueprint medicines investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of blueprint medicines corporation - bpmc

New york city & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of blueprint medicines corporation (nasdaqgs: bpmc) to sanofi (nasdaqgs: sny). under the terms of the proposed transaction, shareholders of blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (cvr) entitling the holder to rece.
GM Ratings Summary
GM Quant Ranking